Cargando…

Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report

INTRODUCTION: We present the case of a 65-year-old woman with multiple and chronic psychosomatic symptoms. Due to motor impairments she was diagnosed in 2009 with Parkinson’s Disease (PD) by the neurology department and empirical treatment with levodopa was prescribed. However, the patient increased...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, M.L., Cerame, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567818/
http://dx.doi.org/10.1192/j.eurpsy.2022.1857
_version_ 1784809494744662016
author Costa, M.L.
Cerame, A.
author_facet Costa, M.L.
Cerame, A.
author_sort Costa, M.L.
collection PubMed
description INTRODUCTION: We present the case of a 65-year-old woman with multiple and chronic psychosomatic symptoms. Due to motor impairments she was diagnosed in 2009 with Parkinson’s Disease (PD) by the neurology department and empirical treatment with levodopa was prescribed. However, the patient increased her levodopa intake by three times the recommended dose. The patient presented many adverse effects, including psychotic symptoms, that were interrupted after the levodopa intake was ended during a two month internament in a psychiatric unit. Dopamine dysregulation syndrome (DDS) is a condition in which patients with PD increase their levodopa intake without an objective worsening of motor symptoms. Higher-than-prescribed doses are taken by patients who develop tolerance and dependence to dopaminergic agonists. OBJECTIVES: To analyse the prevalence of DDS, its diagnosis and treatment as well as the identification of risk factors. METHODS: A case report is presented alongside a review of the relevant literature regarding DDS. RESULTS: The available evidence suggests that the main risk factors for DDS are a history of mood disorders and behavioural disorders, but more studies are needed. Given that DDS is considered a rare adverse effect, physicians usually overlook voluntary dose increase by patients. CONCLUSIONS: DDS, even though uncommon, has severe adverse effects such as dependence and acute psychosis. Before prescription of dopamine agonists, individual risk factors (such as psychiatric comorbidities or history of substance abuse) should be assessed. Also, patients and families should be informed and trained in alarm signs detection. Further studies would be justified to determine DDS prevalence, early diagnosis and treatment. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9567818
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95678182022-10-17 Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report Costa, M.L. Cerame, A. Eur Psychiatry Abstract INTRODUCTION: We present the case of a 65-year-old woman with multiple and chronic psychosomatic symptoms. Due to motor impairments she was diagnosed in 2009 with Parkinson’s Disease (PD) by the neurology department and empirical treatment with levodopa was prescribed. However, the patient increased her levodopa intake by three times the recommended dose. The patient presented many adverse effects, including psychotic symptoms, that were interrupted after the levodopa intake was ended during a two month internament in a psychiatric unit. Dopamine dysregulation syndrome (DDS) is a condition in which patients with PD increase their levodopa intake without an objective worsening of motor symptoms. Higher-than-prescribed doses are taken by patients who develop tolerance and dependence to dopaminergic agonists. OBJECTIVES: To analyse the prevalence of DDS, its diagnosis and treatment as well as the identification of risk factors. METHODS: A case report is presented alongside a review of the relevant literature regarding DDS. RESULTS: The available evidence suggests that the main risk factors for DDS are a history of mood disorders and behavioural disorders, but more studies are needed. Given that DDS is considered a rare adverse effect, physicians usually overlook voluntary dose increase by patients. CONCLUSIONS: DDS, even though uncommon, has severe adverse effects such as dependence and acute psychosis. Before prescription of dopamine agonists, individual risk factors (such as psychiatric comorbidities or history of substance abuse) should be assessed. Also, patients and families should be informed and trained in alarm signs detection. Further studies would be justified to determine DDS prevalence, early diagnosis and treatment. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9567818/ http://dx.doi.org/10.1192/j.eurpsy.2022.1857 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Costa, M.L.
Cerame, A.
Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
title Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
title_full Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
title_fullStr Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
title_full_unstemmed Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
title_short Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
title_sort dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567818/
http://dx.doi.org/10.1192/j.eurpsy.2022.1857
work_keys_str_mv AT costaml dopaminedysregulationsyndromeafterprescriptionofdopamineagonistsacasereport
AT ceramea dopaminedysregulationsyndromeafterprescriptionofdopamineagonistsacasereport